Gilead Sciences to Buy CymaBay Therapeutics for $4.3 Billion
By Colin Kellaher
Gilead Sciences has agreed to buy CymaBay Therapeutics for $4.3 billion in a deal that expands Gilead's liver portfolio.
Gilead on Monday said it will pay $32.50 a share in cash for CymaBay, a nearly 27% premium to Friday's closing price of $25.69 for the Newark, Calif., clinical-stage biopharmaceutical company.
Gilead, a Foster City, Calif., biopharmaceutical company, said the addition of CymaBay's investigational lead product candidate seladelpar for the treatment of primary biliary cholangitis complements its existing liver portfolio.
The U.S. Food and Drug Administration is currently reviewing CymaBay's application seeking approval of seladelpar in primary biliary cholangitis, a chronic and progressive liver disease, with a target action date of Aug. 14.
Gilead said it expects to complete the acquisition in the first quarter.
Trading in shares of CymaBay was halted premarket on Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 12, 2024 08:55 ET (13:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
United States